Islatravir - Merck Sharp & Dohme
Alternative Names: 4-ethynyl-2-fluoro-2-deoxyadenosine; EFdA; MK-8519; MK-8591; MK-8591-eluting implantLatest Information Update: 25 Jul 2024
Price :
$50 *
At a glance
- Originator Merck Sharp & Dohme
- Developer Gilead Sciences; Merck Sharp & Dohme
- Class Alkynes; Antiretrovirals; Fluorinated hydrocarbons; Purine nucleosides; Small molecules
- Mechanism of Action Nucleoside reverse transcriptase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued HIV infections; HIV-1 infections; HIV-2 infections
Most Recent Events
- 25 Jul 2024 Discontinued - Phase-I for HIV infections (SC) , before July 2024 (Merck pipeline, July 2024)
- 25 Jul 2024 Discontinued - Phase-II for HIV-1 infections (Combination therapy) in USA, France, Switzerland (PO), before July 2024 (Merck pipeline, July 2024)
- 25 Jul 2024 Discontinued - Phase-II for HIV-1 infections (Combination therapy, Treatment-experienced) in USA (PO), before July 2024 (Merck pipeline, July 2024)